Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.47 |
| ▸ | RORC | P51449 | 5/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207977 | 0.82 | TACR1 (0.43) | TACR1RORCSLC6A4KCNH2OPRD1 | |
| SCHEMBL3924571 | 0.82 | TACR1 (0.44) | TACR1RORCSLC6A4KCNH2OPRD1 | |
| SCHEMBL4291217 | 0.80 | TACR1 (0.43) | TACR1RORCSLC6A4KCNH2SQOR | |
| SCHEMBL3925943 | 0.80 | TACR1 (0.46) | TACR1RORCSLC6A4KCNH2OPRD1 | |
| SCHEMBL3925962 | 0.78 | TACR1 (0.44) | TACR1RORCSLC6A4KCNH2 | |
| SCHEMBL18280071 | 0.75 | GPR119 (0.47) | DTYMKEPHX2POLB | |
| SCHEMBL3928378 | 0.75 | TACR1 (0.53) | TACR1RORCSLC6A4KCNH2 | |
| SCHEMBL3565915 | 0.73 | POLB (0.50) | DTYMKPOLB | |
| SCHEMBL4027722 | 0.73 | TACR1 (0.55) | TACR1SLC6A4KCNH2 | |
| SCHEMBL3921939 | 0.73 | TACR1 (0.43) | TACR1RORCSLC6A4KCNH2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009633-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |